SEC Comment Letter 0000000000-26-003312 to Cannabis Bioscience International Holdings, Inc. (CBIH)
Cannabis Bioscience International Holdings, Inc.
Date: April 1, 2026 · CIK: 0001411057 · Accession: 0000000000-26-003312
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 024-12731
Letter
Re: Cannabis Bioscience International Holdings, Inc. Offering Statement on Form 1-A Filed March 27, 2026 File No. 024-12731 Dear Dante Picazo:
April 1, 2026
Dante Picazo Principal Executive Officer Cannabis Bioscience International Holdings, Inc. 6201 Bonhomme Road Suite 435N Houston, TX 77036
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification.
We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report.
Please contact Robert Augustin at 202-551-8483 with any questions.
Sincerely,
Division of
Corporation Finance
Office of
Industrial Applications and Services
cc: Barry J. Miller
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 1, 2026 Dante Picazo Principal Executive Officer Cannabis Bioscience International Holdings, Inc. 6201 Bonhomme Road Suite 435N Houston, TX 77036 Re: Cannabis Bioscience International Holdings, Inc. Offering Statement on Form 1-A Filed March 27, 2026 File No. 024-12731 Dear Dante Picazo: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report. Please contact Robert Augustin at 202-551-8483 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Barry J. Miller </TEXT> </DOCUMENT>